129 related articles for article (PubMed ID: 36193866)
1. A meta-analytic framework to adjust for bias in external control studies.
Incerti D; Bretscher MT; Lin R; Harbron C
Pharm Stat; 2023 Jan; 22(1):162-180. PubMed ID: 36193866
[TBL] [Abstract][Full Text] [Related]
2. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
Colditz GA
Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580
[TBL] [Abstract][Full Text] [Related]
3. Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers.
Thorlund K; Duffield S; Popat S; Ramagopalan S; Gupta A; Hsu G; Arora P; Subbiah V
J Comp Eff Res; 2024 Mar; 13(3):e230147. PubMed ID: 38205741
[TBL] [Abstract][Full Text] [Related]
4. Linezolid for drug-resistant pulmonary tuberculosis.
Singh B; Cocker D; Ryan H; Sloan DJ
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012836. PubMed ID: 30893466
[TBL] [Abstract][Full Text] [Related]
5. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
6. Conditional borrowing external data to establish a hybrid control arm in randomized clinical trials.
Li H; Tiwari R; Li QH
J Biopharm Stat; 2022 Nov; 32(6):954-968. PubMed ID: 35067183
[TBL] [Abstract][Full Text] [Related]
7. A proper statistical inference framework to compare clinical trial and real-world progression-free survival data.
Zhu J; Tang RS
Stat Med; 2022 Dec; 41(29):5738-5752. PubMed ID: 36199170
[TBL] [Abstract][Full Text] [Related]
8. Clarifying selection bias in cluster randomized trials.
Li F; Tian Z; Bobb J; Papadogeorgou G; Li F
Clin Trials; 2022 Feb; 19(1):33-41. PubMed ID: 34894795
[TBL] [Abstract][Full Text] [Related]
9. Quantifying over-estimation in early stopped clinical trials and the "freezing effect" on subsequent research.
Wang H; Rosner GL; Goodman SN
Clin Trials; 2016 Dec; 13(6):621-631. PubMed ID: 27271682
[TBL] [Abstract][Full Text] [Related]
10. Use of quantitative bias analysis to evaluate single-arm trials with real-world data external controls.
Gray C; Ralphs E; Fox MP; Lash TL; Liu G; Kou TD; Rivera DR; Bosco J; Braun KVN; Grimson F; Layton D
Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5796. PubMed ID: 38680093
[TBL] [Abstract][Full Text] [Related]
11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
12. Case weighted power priors for hybrid control analyses with time-to-event data.
Kwiatkowski E; Zhu J; Li X; Pang H; Lieberman G; Psioda MA
Biometrics; 2024 Mar; 80(2):. PubMed ID: 38536747
[TBL] [Abstract][Full Text] [Related]
13. Applying the estimand and target trial frameworks to external control analyses using observational data: a case study in the solid tumor setting.
Polito L; Liang Q; Pal N; Mpofu P; Sawas A; Humblet O; Rufibach K; Heinzmann D
Front Pharmacol; 2024; 15():1223858. PubMed ID: 38344177
[No Abstract] [Full Text] [Related]
14. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions.
Page MJ; McKenzie JE; Kirkham J; Dwan K; Kramer S; Green S; Forbes A
Cochrane Database Syst Rev; 2014 Oct; 2014(10):MR000035. PubMed ID: 25271098
[TBL] [Abstract][Full Text] [Related]
15. Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms.
Burcu M; Dreyer NA; Franklin JM; Blum MD; Critchlow CW; Perfetto EM; Zhou W
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1228-1235. PubMed ID: 32162381
[TBL] [Abstract][Full Text] [Related]
16. Indirect comparisons of competing interventions.
Glenny AM; Altman DG; Song F; Sakarovitch C; Deeks JJ; D'Amico R; Bradburn M; Eastwood AJ;
Health Technol Assess; 2005 Jul; 9(26):1-134, iii-iv. PubMed ID: 16014203
[TBL] [Abstract][Full Text] [Related]
17. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747
[TBL] [Abstract][Full Text] [Related]
18. Evaluating non-randomised intervention studies.
Deeks JJ; Dinnes J; D'Amico R; Sowden AJ; Sakarovitch C; Song F; Petticrew M; Altman DG; ;
Health Technol Assess; 2003; 7(27):iii-x, 1-173. PubMed ID: 14499048
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
